Gamma-delta T cells in neuroblastoma: Exploiting MHC-independent recognition to overcome the barriers of high-risk disease

Neuroblastoma is the most frequent extracranial solid tumor in children and the main cause of early childhood cancer deaths. Relapse occurs in more than half of high-risk patients despite rigorous multimodal therapy, and four-year overall survival in relapsed disease is approximately 20%. Anti-GD2 monoclonal antibodies and GD2-directed CAR T cell treatment have advanced the field, although neither has eliminated neuroblastoma's immune resistance. Current immunotherapy has three interrelated challenges. GD2 heterogeneity lets antigen-negative subclones escape and cause recurrence. Inhibitory cytokines, regulatory T cells, and myeloid-derived suppressor cells dominate the TME. MHC class I downregulation frequently renders traditional αβ T cell methods ineffective, even with the target antigen present. Gamma-delta (γδ) T cells offer a distinct mechanism. They recognize tumor targets without antigen presentation by sensing stress-induced ligands through NKG2D and DNAM-1 and phosphoantigens through butyrophilin proteins BTN3A1 and BTN2A1. This recognition holds regardless of MHC class I status. In conjunction with anti-GD2 antibodies, CD16 expression boosts antibody-dependent cellular cytotoxicity. In neuroblastoma lesions, γδ T cells are the primary antitumoral fraction in tumor-infiltrating lymphocyte products, indicating compatibility with the disease's immune system. This study examines neuroblastoma immunotherapy failure mechanisms and innovative γδ T cell platforms, such as non-engineered allogeneic products, composite γδ T plus NK cell techniques, and CAR- and AbTCR-modified designs. A biomarker-driven patient selection paradigm and product standardization, in vivo persistence, and TME suppression are examined. NCT05400603, the first trial of adoptive transfer of ex vivo-expanded allogeneic γδ T cells in a population that includes pediatric neuroblastoma patients, is crucial for proving the mechanism.

Authors

Institutions

Publication Details

Journal
Translational Oncology
Published
2026-11-16
DOI
https://doi.org/10.1016/j.tranon.2026.103122
Primary Topic
Neuroblastoma Research and Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Gamma-delta T cells in neuroblastoma: Exploiting MHC-independent recognition to overcome the barriers of high-risk disease

Zahra Karimizadeh, Amirali Kalantari, Samira Mohamadian, Maryam Behfar et al.
Translational Oncology
Neuroblastoma Research and Treatments
article

Gamma-delta T cells in neuroblastoma: Exploiting MHC-independent recognition to overcome the barriers of high-risk disease

Zahra Karimizadeh, Amirali Kalantari, Samira Mohamadian, Maryam Behfar, Amir Ali Hamidieh, Hamid Farajifard, Rashin Mohseni, Nafiseh Esmaeil, Mitra Ardakani Moghadam
article en

Abstract

Neuroblastoma is the most frequent extracranial solid tumor in children and the main cause of early childhood cancer deaths. Relapse occurs in more than half of high-risk patients despite rigorous multimodal therapy, and four-year overall survival in relapsed disease is approximately 20%. Anti-GD2 monoclonal antibodies and GD2-directed CAR T cell treatment have advanced the field, although neither has eliminated neuroblastoma's immune resistance. Current immunotherapy has three interrelated challenges. GD2 heterogeneity lets antigen-negative subclones escape and cause recurrence. Inhibitory cytokines, regulatory T cells, and myeloid-derived suppressor cells dominate the TME. MHC class I downregulation frequently renders traditional αβ T cell methods ineffective, even with the target antigen present. Gamma-delta (γδ) T cells offer a distinct mechanism. They recognize tumor targets without antigen presentation by sensing stress-induced ligands through NKG2D and DNAM-1 and phosphoantigens through butyrophilin proteins BTN3A1 and BTN2A1. This recognition holds regardless of MHC class I status. In conjunction with anti-GD2 antibodies, CD16 expression boosts antibody-dependent cellular cytotoxicity. In neuroblastoma lesions, γδ T cells are the primary antitumoral fraction in tumor-infiltrating lymphocyte products, indicating compatibility with the disease's immune system. This study examines neuroblastoma immunotherapy failure mechanisms and innovative γδ T cell platforms, such as non-engineered allogeneic products, composite γδ T plus NK cell techniques, and CAR- and AbTCR-modified designs. A biomarker-driven patient selection paradigm and product standardization, in vivo persistence, and TME suppression are examined. NCT05400603, the first trial of adoptive transfer of ex vivo-expanded allogeneic γδ T cells in a population that includes pediatric neuroblastoma patients, is crucial for proving the mechanism.

Translational OncologyVol. 75
Isfahan University of Medical Sciences (IR), Children's Medical Center (IR), Tehran University of Medical Sciences (IR)
Neuroblastoma Research and Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon